{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:55:34Z","timestamp":1792788934347,"version":"4.5.0"},"reference-count":39,"publisher":"Informa UK Limited","issue":"18","funder":[{"name":"TETFUND Nigeria"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.2217\/pgs-2020-0081","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T04:29:19Z","timestamp":1606451359000},"page":"1289-1297","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Effect of\n                    <i>CYP3A5<\/i>\n                    *3 Genotypes on Lumefantrine Plasma Concentrations Among Malaria-HIV-Infected Women"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-2641","authenticated-orcid":false,"given":"Adebanjo J","family":"Adegbola","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Obafemi Awolowo University, Ile Ife, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1470-7483","authenticated-orcid":false,"given":"Julius O","family":"Soyinka","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Obafemi Awolowo University, Ile Ife, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluseye O","family":"Bolaji","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Obafemi Awolowo University, Ile Ife, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"e_1_3_3_2_1","volume-title":"World Malaria Report 2019","author":"WHO","year":"2019","unstructured":"WHO . World Malaria Report 2019. World Health Organization, Geneva, Switzerland (2019)."},{"key":"e_1_3_3_3_1","first-page":"30","volume-title":"Guidelines for the Treatment of Malaria (3rd Edition).","author":"WHO","year":"2015","unstructured":"WHO . Guidelines for the Treatment of Malaria (3rd Edition).Geneva, Switzerland, 30\u201345 (2015)."},{"key":"e_1_3_3_4_1","first-page":"703730","article-title":"Artemether-lumefantrine combination therapy for treatment of uncomplicated malaria: the potential for complex interactions with antiretroviral drugs in HIV-infected individuals","volume":"2011","author":"Byakika-Kibwika P","year":"2011","unstructured":"Byakika-Kibwika P , LamordeM , Mayanja-KizzaH , KhooS , MerryC , van GeertruydenJ-P. Artemether-lumefantrine combination therapy for treatment of uncomplicated malaria: the potential for complex interactions with antiretroviral drugs in HIV-infected individuals. Malar. Res. Treat.2011, 703730 (2011).","journal-title":"Malar. Res. Treat."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01605-15"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01252-18"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw291"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks207"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000401"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00868-17"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2016.09.005"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2016.11.034"},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejpb.2015.10.001","article-title":"In vivo efficacy and bioavailability of lumefantrine: evaluating the application of Pheroid technology","volume":"97","author":"Du Plessis LH","year":"2015","unstructured":"Du Plessis LH , GovenderK , DentiP , WiesnerL. In vivo efficacy and bioavailability of lumefantrine: evaluating the application of Pheroid technology. Eur. J. Pharm. Biopharm.97(Pt A), 68\u201377 (2015).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.61.05.0002"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01700-12"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2016.07.012"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2015.37"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.119.088062"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2013.10.037"},{"key":"e_1_3_3_20_1","unstructured":"FDA . Bioanalytical method validation guidance for industry. (2018). http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2340-3"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936"},{"key":"e_1_3_3_23_1","first-page":"13","volume-title":"Malaria Policy Advisory Committee Meeting (WHO\/HTM\/GMP\/MPAC\/2015.13)","author":"WHO","year":"2015","unstructured":"WHO . Malaria in Pregnancy. WHO Evidence Review Group Meeting report. Malaria Policy Advisory Committee Meeting (WHO\/HTM\/GMP\/MPAC\/2015.13)Geneva, Switzerland, 13\u201316 (2015)."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-291"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002928"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw338"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.59"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01153-15"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002579"},{"issue":"10","key":"e_1_3_3_30_1","doi-asserted-by":"crossref","first-page":"e00518","DOI":"10.1128\/AAC.00518-18","article-title":"Population pharmacokinetics of artemether, dihydroartemisinin, and lumefantrine in rwandese pregnant women treated for uncomplicated malaria","volume":"62","author":"Lohy Das J","year":"2018","unstructured":"Lohy Das J , RulisaS , DeVries PJet al. Population pharmacokinetics of artemether, dihydroartemisinin, and lumefantrine in rwandese pregnant women treated for uncomplicated malaria. Antimicrob. Agents Chemother.62(10), e00518\u2013e00518 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00683-13"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.690"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2016.09.001"},{"issue":"267","key":"e_1_3_3_34_1","first-page":"1","article-title":"Effect of Pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women","volume":"16","author":"Mutagonda RF","year":"2017","unstructured":"Mutagonda RF , KamuhawaAAR , MinziOMSet al. Effect of Pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Malar. J.16(267), 1\u201310 (2017).","journal-title":"Malar. J."},{"key":"e_1_3_3_35_1","unstructured":"FDA . Guidance for industry bioavailability and bioequivalence studies submitted in NDAs or INDs-general considerations. (2014). http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000230411.89973.1b"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181da79d6"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2017.03.093"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-37112-6"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0695-2"}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/pgs-2020-0081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T18:37:36Z","timestamp":1715971056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/pgs-2020-0081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":39,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.2217\/pgs-2020-0081"],"URL":"https:\/\/doi.org\/10.2217\/pgs-2020-0081","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgs20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}